Nurix Therapeutics, Inc. (NRIX) Earnings Call Transcripts
Nurix Therapeutics, Inc.'s Latest Earnings Call - May 20, 2026
In the Q1 2026 earnings call for Nurix Therapeutics, Inc. (NRIX), management highlighted significant advancements in their lead program, Bexdeg, particularly in treating chronic lymphocytic leukemia (CLL). The company reported a strong objective response rate of 83% and a progression-free survival of 22.1 months in heavily pre-treated patients. Management maintained their guidance for ongoing trials and indicated plans to file for accelerated approval in the near future. Overall, the call underscored the potential for Bexdeg to become a leading treatment option in both CLL and autoimmune indications, which could drive future revenue growth.
Reported metrics
| Metric | Value |
|---|---|
| Objective Response Rate | 83% (beat) |
| Progression-Free Survival | 22.1 months (beat) |
| Phase II Enrollment Target | 100 patients (inline) |
| IND Filing Timeline | Second half of 2026 (inline) |
| Upcoming Data Presentation | EHA meeting in June 2026 (neutral) |
Guidance from management
Management maintained their guidance for ongoing trials and indicated plans for accelerated approval filings in the near future, particularly for Bexdeg in CLL and autoimmune diseases.
What management said
Head-to-head versus [ PEO ], and that's going to be in second-line patients, so patients that have seen a prior BTK covalent agent. And they may have seen other agents, but the minimum is that they have taken the covalent BTK inhibitor. So that's kicking off midyear this year.
Right. We've not done any liver tox issue. So we think we can bring our safe profile there. We also think -- yes, and the inhibitors like [ eneubrutinib, palbrutinib ] have shown efficacy, essentially proof of concept established for the BTK mechanism. But we think we can enhance efficacy also because, again, we're taking out not just the kinase function, but the scaffolding function, which we believe is operating in...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for Bexdeg, particularly how it will differentiate itself from other BTK degraders. There were also questions about the timeline for trial initiations and the potential for partnership strategies.
Main topics on the call
- Bexdeg's Clinical Efficacy — Management reported an impressive 83% overall objective response rate in CLL patients, indicating strong efficacy. CEO Arthur Sands stated, 'we're seeing high response rates in these patients,' which suggests a competiti...
- Upcoming Data Presentation — The company is set to present new data at the European Hematology Association meeting, focusing on the consistency of high response rates and safety. Jason Kantor noted, 'we continue to see very high objective response r...
- Phase II and III Trials — Nurix is progressing with a Phase II study targeting late-line CLL patients and plans to initiate a Phase III trial head-to-head against pirtobrutinib. Sands mentioned, 'we believe that defines an unmet medical need popu...
- Expansion into Autoimmune Indications — Management discussed the potential for Bexdeg in autoimmune diseases, with plans to file an IND in the second half of 2026. Sands highlighted, 'we think that it has expansive opportunity in I&I,' indicating a strategic p...
Read the full Nurix Therapeutics, Inc. transcript (May 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 22 calls on record spanning May 14, 2024 to June 8, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 22 Nurix Therapeutics, Inc. earnings call transcripts on record, spanning May 14, 2024 to June 8, 2026. Based on this history, Nurix Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NRIX
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 22
- First call
- May 14, 2024
- Most recent
- June 8, 2026
- Reporting cadence
- quarterly